https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2005-05-01 / J. Clin. Oncol. 2005 May;23(13):3079-85
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2005-05-01 / J. Clin. Oncol. 2005 May;23(13):3079-852005-05-01 00:00:002005-05-01 00:00:00Randomized trial of hyperthermia and radiation for superficial tumors
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2005-03-18 / Vaccine 2005 Mar;23(17-18):2367-73
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2005-03-18 / Vaccine 2005 Mar;23(17-18):2367-732005-03-18 00:00:002019-02-15 09:19:58Tumour-dendritic hybrid cell vaccination for the treatment of patients with malignant melanoma: immunological effects and clinical results
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2005-01-01 / Immunol. Invest. 2005;34(3):245-58
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2005-01-01 / Immunol. Invest. 2005;34(3):245-582005-01-01 00:00:002005-01-01 00:00:00Comparison of the anti-tumor effects of various whole-body hyperthermia protocols: correlation with HSP 70 expression and composition of splenic lymphocytes
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2005-01-01 / Curr. Pharm. Des. 2005;11(27):3461-73
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2005-01-01 / Curr. Pharm. Des. 2005;11(27):3461-732005-01-01 00:00:002019-02-15 09:19:57Melanoma immunotherapy: past, present, and future
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2004-10-01 / Cancer Biother. Radiopharm. 2004 Oct;19(5):658-65
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2004-10-01 / Cancer Biother. Radiopharm. 2004 Oct;19(5):658-652004-10-01 00:00:002019-02-15 09:19:59Phase I/II trial of melanoma patient-specific vaccine of proliferating autologous tumor cells, dendritic cells, and GM-CSF: planned interim analysis
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2004-08-23 / BMC Cancer 2004 Aug;4:53
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2004-08-23 / BMC Cancer 2004 Aug;4:532004-08-23 00:00:002004-08-23 00:00:00The impact of surgery and mild hyperthermia on tumor response and angioneogenesis of malignant melanoma in a rat perfusion model
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2004-08-01 / Ai Zheng 2004 Aug;23(8):910-3
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2004-08-01 / Ai Zheng 2004 Aug;23(8):910-32004-08-01 00:00:002019-02-15 09:20:00[Antitumor research on mouse melanoma with combined application of Newcastle disease virus and its HN gene]
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2004-07-10 / Int. J. Cancer 2004 Jul;110(5):730-40
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2004-07-10 / Int. J. Cancer 2004 Jul;110(5):730-402004-07-10 00:00:002019-02-15 09:20:01Vaccination with hybrids of tumor and dendritic cells induces tumor-specific T-cell and clinical responses in melanoma stage III and IV patients
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2003-10-15 / J. Clin. Oncol. 2003 Oct;21(20):3826-35
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2003-10-15 / J. Clin. Oncol. 2003 Oct;21(20):3826-352003-10-15 00:00:002019-02-15 08:49:35Intranodal administration of peptide-pulsed mature dendritic cell vaccines results in superior CD8+ T-cell function in melanoma patients
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2003-10-01 / Melanoma Res. 2003 Oct;13(5):521-30
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2003-10-01 / Melanoma Res. 2003 Oct;13(5):521-302003-10-01 00:00:002019-02-15 08:49:36Results of a phase I clinical study using autologous tumour lysate-pulsed monocyte-derived mature dendritic cell vaccinations for stage IV malignant melanoma patients combined with low dose interleukin-2
